New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?

Vesa M. Olkkonen, Juha Sinisalo, Matti Jauhiainen

Research output: Contribution to journalReview Articlepeer-review

Original languageEnglish
JournalAtherosclerosis
Volume272
Pages (from-to)27-32
Number of pages6
ISSN0021-9150
DOIs
Publication statusPublished - May 2018
MoE publication typeA2 Review article in a scientific journal

Fields of Science

  • 3111 Biomedicine
  • 3121 General medicine, internal medicine and other clinical medicine
  • ANGPTL3
  • Antibody therapy
  • apoC-III
  • ASO
  • CVD
  • TRL
  • CORONARY EVENTS
  • ANGIOPOIETIN-LIKE PROTEINS
  • OF-FUNCTION MUTATIONS
  • LOW-DENSITY LIPOPROTEINS
  • METABOLISM
  • ENDOTHELIAL-CELLS
  • B GENE
  • APOLIPOPROTEIN-C-III
  • FAMILIAL COMBINED HYPOLIPIDEMIA
  • PLASMA TRIGLYCERIDES

Cite this